Amid Ozempic's 'Miracle' Weight-Loss Craze, This Company Peaked Over 100% In Tuesday Pre-Market After Receiving US Patent For Obesity Treatment
Portfolio Pulse from Pooja Rajkumari
ReShape Lifesciences Inc. (NASDAQ:RSLS) saw its stock surge over 100% in pre-market trading after receiving approval from the U.S. Patent And Trademark Office for its obesity treatment devices. The approval is subject to a fee due on Aug. 26, 2024. This comes amid increasing demand for weight-loss drugs like Ozempic and WeGovy. At the time of writing, RSLS was trading 82.87% higher at $0.380.
May 29, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ReShape Lifesciences Inc. (NASDAQ:RSLS) received approval from the U.S. Patent And Trademark Office for its obesity treatment devices, causing its stock to surge over 100% in pre-market trading. The approval is subject to a fee due on Aug. 26, 2024. The stock is currently up 82.87% at $0.380.
The approval of the patent for ReShape's obesity treatment devices is a significant milestone, likely to boost investor confidence and drive the stock price up in the short term. The current surge in pre-market trading reflects this positive sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100